Scientists and doctors from Ukraine, the United States and Italy exchanged the results of the latest scientific research in the fight against coronavirus and confirmed the effectiveness of antiviral drugs in the fight against COVID-19.
“The problem of combating the pandemic is relevant both for Ukraine and for the whole world. In our country, the number of COVID-19 cases is growing daily. And although the immunization of the population is quite active, none of the vaccines guarantees that a person will not get sick. The issue of prevention and treatment of COVID-19 in the early stages is now extremely relevant,” the scientists said, following the results of the scientific and practical conference entitled “New Treatment Strategies for COVID-19,” organized by the pharmaceutical company Farmak (Kyiv).
At the conference, scientists discussed the development of new and effective existing medicines that help treat patients with COVID-19. In particular, they paid special attention to the results of studies of antiviral drugs that demonstrated a therapeutic effect, shared their experience of partnership in the development of a direct-acting antiviral drug, talked about the prospects for the development of other antiviral drugs.
“How do antiviral drugs work? The virus is much smaller than bacteria, but this does not prevent it from destroying cells. People often mistakenly believe that antibiotics can neutralize the virus, but this is not the case. It is important to understand that antibiotics are effective only against certain types of bacteria. Antiviral agents are used to quickly and effectively deal with the virus. At the beginning of the disease, they reduce the symptoms and shorten the duration of the disease. It should also be understood that such drugs prevent it from multiplying,” the scientists said.
Italian scientist, doctor of the Ronzoni Institute for Chemical and Biochemical Research Stefano Elli, in particular, said that antiviral drugs have great potential in the fight against a pandemic. He presented a study showing the effect of Enisamium on SARS-CoV-2 (the virus that causes COVID-19). Enisamium is better known as the active ingredient of Farmak pharmaceutical company.
“According to the results of preclinical and clinical studies, Enisamium has confirmed its effectiveness. Prescribing the drug to patients with moderate severity of COVID-19 made it possible to alleviate the course of the disease in the subjects, prevent the deterioration of its clinical condition, avoid deaths and shorten the length of hospital stay,” Elli said.
According to the representative of the state enterprise State Expert Center Pavlo Babich, the positive experience of using this drug is confirmed by the results of a study on its use among patients with moderate COVID-19.
“Studies have shown that an antiviral drug successfully used in the treatment of influenza and acute respiratory viral infections in 11 countries of the world and, as it was recently established, by the joint efforts of scientists from Ukraine, Germany, the U.K., is also clinically effective in moderate COVID-19. Indeed, the drug has a wide spectrum of antiviral action against RNA viruses that cause acute respiratory diseases by inhibiting the RNA polymerase enzyme of the virus, under the influence of which it replicates,” he said.
“According to the results of research by scientists from the United States, Italy and Ukraine, it can be summarized that antiviral drugs are a powerful weapon in overcoming and preventing the negative consequences of COVID-19,” the scientists said.
The independent laboratory Invitro will conduct research on the effectiveness of the vaccine CoviShield/AstraZeneca, a press release of the company says.
Head of the laboratory’s clinical diagnostic complex Pavlo Naboka said that the study will consist in checking the amount of antibodies that were produced after vaccination.
“According to the official instructions, the principle of action of the CoviShield vaccine is based on the development of specific immunity to the S-protein (spike) of the SARS-CoV-2 coronavirus (the causative agent of COVID-19). The presence of a sufficient amount of antibodies to this protein is a factor that protects a person from the development of the disease even in case of infection. It is possible to check how many antibodies have developed in the body after vaccination by using a new laboratory test by the world famous manufacturer Abbott Diagnostics to quantify the level of neutralizing (protective) antibo
During the entire COVID-19 vaccination process, blood samples will be taken from laboratory staff to monitor immune levels, he said. That is, the laboratory will assess how many antibodies to SARS-CoV-2 will appear in a person after the first and second vaccinations, at what rate of antibodies will be produced, whether the actual concentration of antibodies will correspond to the data reported by the vaccine manufacturer.
According to the instructions, a sufficient level of antibodies should be formed within 90 days after the first administration of the vaccine. That is, the laboratory Invitro will be able to announce the results of the study in the summer of 2021.
AstraZeneca, COVISHIELD, EFFECTIVENESS, INDEPENDENT LABORATORY, VACCINE